SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    H. Fontaine, S. Kahi, C. Chazallon, M. Bourgine, A. Varaut, C. Buffet, O. Godon, J. F. Meritet, Y. Saidi, M. L. Michel, D. Scott-Algara, J. P. Aboulker, S. Pol, Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN, Gut, 2015, 64, 1, 139

    CrossRef

  2. 2
    Haiqing Wu, Gangde Zhao, Fangxing Qian, Kehui Liu, Jingdong Xie, Huijuan Zhou, Jie Xu, Yumin Xu, Yan Han, Qing Xie, Hui Wang, Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B, Liver International, 2015, 35,
  3. 3
    Q. Xie, H. Zhou, X. Bai, S. Wu, J.-J. Chen, J. Sheng, Y. Xie, C. Chen, H. L.-Y. Chan, M. Zhao, A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B, Clinical Infectious Diseases, 2014, 59, 12, 1714

    CrossRef

  4. 4
    Suna Yapali, Ilker Turan, Omer Ozutemiz, Oktay Tekesin, A severe case of esophageal ulcer causing a tight stricture despite long-term D-penicillamine treatment, Wiener klinische Wochenschrift, 2014, 126, 23-24, 789

    CrossRef

  5. 5
    Xiaoping Xie, Shuang Geng, Hu Liu, Chaofan Li, Yuqin Yang, Bin Wang, Cimetidine synergizes with Praziquantel to enhance the immune response of HBV DNA vaccine via activating cytotoxic CD8+T cell, Human Vaccines & Immunotherapeutics, 2014, 10, 6, 1688

    CrossRef

  6. 6
    G. L.-H. Wong, V. W.-S. Wong, H. L.-Y. Chan, Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B, Journal of Viral Hepatitis, 2014, 21, 12
  7. You have free access to this content7
    Maria Buti, HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs?, Liver International, 2014, 34,
  8. 8
    Margo J. H. van Campenhout, Harry L. A. Janssen, How to achieve immune control in chronic hepatitis B?, Hepatology International, 2014,

    CrossRef

  9. 9
    Tung-Hung Su, Jia-Horng Kao, Improving clinical outcomes of chronic hepatitis B virus infection, Expert Review of Gastroenterology & Hepatology, 2014, 1

    CrossRef

  10. 10
    Bhupesh Singla, Anuradha Chakraborti, Bal Krishan Sharma, Shweta Kapil, Yogesh K. Chawla, Sunil K. Arora, Ashim Das, Radha K. Dhiman, Ajay Duseja, Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients, Molecular Biology Reports, 2014, 41, 7, 4689

    CrossRef

  11. 11
    Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Norio Akuta, Hitomi Sezaki, Tasuku Hara, Yusuke Kawamura, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Sachiyo Watahiki, Rie Mineta, Hiromitsu Kumada, Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine, Journal of Gastroenterology, 2014, 49, 6, 1094

    CrossRef

  12. You have free access to this content12
    Cristina Pérez-Cameo, Mònica Pons, Rafael Esteban, New therapeutic perspectives in HBV: when to stop NAs, Liver International, 2014, 34,
  13. 13
    W. P. Brouwer, M. J. Sonneveld, F. Tabak, K. Simon, Y. Cakaloglu, U. S. Akarca, S. Zeuzem, P. Ferenci, J. E. Heathcote, R. J. Knegt, A. Boonstra, B. E. Hansen, H. L. A. Janssen, Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2014, 40, 7
  14. 14
    A. F. Stättermayer, T. Scherzer, S. Beinhardt, K. Rutter, H. Hofer, P. Ferenci, Review article: genetic factors that modify the outcome of viral hepatitis, Alimentary Pharmacology & Therapeutics, 2014, 39, 10
  15. 15
    Rama Kapoor, Shyam Kottilil, Strategies to eliminate HBV infection, Future Virology, 2014, 9, 6, 565

    CrossRef

  16. 16
    Qin Ning, Meifang Han, Yongtao Sun, Jiaji Jiang, Deming Tan, Jinlin Hou, Hong Tang, Jifang Sheng, Mianzhi Zhao, Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial), Journal of Hepatology, 2014, 61, 4, 777

    CrossRef

  17. 17
    Phunchai Charatcharoenwitthaya, Teerha Piratvisuth, Baseline and On-treatment Predictors of Chronic Hepatitis B Patients Receiving Pegylated Interferon Therapy in Asia, Current Hepatitis Reports, 2013, 12, 3, 165

    CrossRef

  18. 18
    Zhen Huan Cao, Li Na Ma, Hong Wei Zhang, Ya Li Liu, Xin Yue Chen, Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion, Journal of Digestive Diseases, 2013, 14, 8
  19. 19
    Milan J. Sonneveld, Vincent Rijckborst, Louwerens Zwang, Stefan Zeuzem, E. Jenny Heathcote, Krzysztof Simon, Roeland Zoutendijk, Ulus S. Akarca, Suzan D. Pas, Bettina E. Hansen, Harry L.A. Janssen, Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants, Antiviral Research, 2013, 97, 3, 312

    CrossRef

  20. 20
    Teerha Piratvisuth, Patrick Marcellin, Matei Popescu, Hans-Peter Kapprell, Vivien Rothe, Zhi-Meng Lu, Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients, Hepatology International, 2013, 7, 2, 429

    CrossRef

  21. 21
    Masahiko Yano, Shogo Ohkoshi, Yo-hei Aoki, Hiromichi Takahashi, Sou Kurita, Kazuhide Yamazaki, Kenta Suzuki, Satoshi Yamagiwa, Ayumi Sanpei, Shun Fujimaki, Toshifumi Wakai, Shin-ei Kudo, Yasunobu Matsuda, Yutaka Aoyagi, Hepatitis B virus X induces cell proliferation in the hepatocarcinogenesis via up-regulation of cytoplasmic p21 expression, Liver International, 2013, 33, 8
  22. 22
    Jacinta A Holmes, Tin Nguyen, Dilip Ratnam, Neel M Heerasing, Jane V Tehan, Sara Bonanzinga, Anouk Dev, Sally Bell, Stephen Pianko, Robert Chen, Kumar Visvanathan, Rachel Hammond, David Iser, Ferry Rusli, William Sievert, Paul V Desmond, D Scott Bowden, Alexander J Thompson, IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α, Journal of Gastroenterology and Hepatology, 2013, 28, 5
  23. 23
    Ching-Lung Lai, Man-Fung Yuen, Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy, Hepatology, 2013, 57, 1
  24. 24
    P. Arends, H. L. A. Janssen, Response Guided Treatment for Peginterferon in Chronic Hepatitis B, Current Hepatitis Reports, 2013, 12, 2, 88

    CrossRef

  25. 25
    Milan J. Sonneveld, Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry L.-Y. Chan, Harry L.A. Janssen, Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels, Hepatology, 2013, 58, 3
  26. 26
    H. Lyu, D. Lee, Y.-H. Chung, J. A. Kim, J.-H. Lee, Y.-J. Jin, W. Park, P. Mathews, E. Jaffee, L. Zheng, E. Yu, Y. J. Lee, Synergistic Effects of A1896, T1653 and T1762/A1764 Mutations in Genotype C2 Hepatitis B Virus on Development of Hepatocellular Carcinoma, Journal of Viral Hepatitis, 2013, 20, 3
  27. 27
    Bo Liu, Xin Wen, Canhua Huang, Yuquan Wei, Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years, The International Journal of Biochemistry & Cell Biology, 2013, 45, 9, 1987

    CrossRef

  28. 28
    Danbi Lee, Young-Hwa Chung, Sae Hwan Lee, Sung Eun Kim, Yoon-Seon Lee, Kang Mo Kim, Young Suk Lim, Han Chu Lee, Yung Sang Lee, Eunsil Yu, Effect of Response to Interferon-a Therapy on the Occurrence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B, Digestive Diseases, 2012, 30, 6, 568

    CrossRef

  29. 29
    Dilip Ratnam, Anouk Dev, Tin Nguyen, Vijaya Sundararajan, Hugh Harley, Wendy Cheng, Alice Lee, Ferry Rusli, Robert Chen, Sally Bell, Stephen Pianko, William Sievert, Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: A multicenter clinical experience, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  30. 30
    KASL Clinical Practice Guidelines: Management of chronic hepatitis B, Clinical and Molecular Hepatology, 2012, 18, 2, 109

    CrossRef

  31. 31
    Fumitaka Suzuki, Yasuji Arase, Yoshiyuki Suzuki, Norio Akuta, Hitomi Sezaki, Yuya Seko, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada, Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan, Journal of Gastroenterology, 2012, 47, 7, 814

    CrossRef

  32. 32
    Takashi Toyama, Hisashi Ishida, Hiromi Ishibashi, Hiroshi Yatsuhashi, Makoto Nakamuta, Masaaki Shimada, Hajime Ohta, Takeaki Satoh, Michio Kato, Taizo Hijioka, Hirotsugu Takano, Toshiki Komeda, Michiyasu Yagura, Hiroshi Mano, Yukio Watanabe, Masakazu Kobayashi, Eiji Mita, Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B, Hepatology Research, 2012, 42, 12
  33. 33
    Milan J. Sonneveld, Vincent W.–S. Wong, Andrea M. Woltman, Grace L.H. Wong, Yilmaz Cakaloglu, Stefan Zeuzem, Erik H.C.J. Buster, Andre G. Uitterlinden, Bettina E. Hansen, Henry L.Y. Chan, Harry L.A. Janssen, Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B, Gastroenterology, 2012, 142, 3, 513

    CrossRef

  34. 34
    Xinyue Chen, Zhenhuan Cao, Yali Liu, Hongwei Zhang, Yonghong Zhang, Lina Ma, Yi Jin, Haibin Yu, Bing Ma, Yanhong Zheng, Hao Wu, Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog, Journal of Gastroenterology and Hepatology, 2012, 27, 3
  35. 35
    Mauro Viganò, Pietro Lampertico, Antiviral drugs for HBV liver disease, Expert Opinion on Biological Therapy, 2011, 11, 3, 285

    CrossRef

  36. 36
    Ke-Qin Hu, Calvin Q. Pan, Diane Goodwin, Barriers to Screening for Hepatitis B Virus Infection in Asian Americans, Digestive Diseases and Sciences, 2011, 56, 11, 3163

    CrossRef

  37. 37
    Ju Dong Yang, W. Ray Kim, Ritika Coelho, Teresa A. Mettler, Joanne T. Benson, Schuyler O. Sanderson, Terry M. Therneau, Bohyun Kim, Lewis R. Roberts, Cirrhosis Is Present in Most Patients With Hepatitis B and Hepatocellular Carcinoma, Clinical Gastroenterology and Hepatology, 2011, 9, 1, 64

    CrossRef

  38. 38
    Chao-Wei Hsu, Chau-Ting Yeh, Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy, Hepatology, 2011, 54, 1
  39. 39
    Bettina E. Hansen, Vincent Rijckborst, Martijn J. ter Borg, Harry L.A. Janssen, HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo, Journal of Medical Virology, 2011, 83, 11
  40. 40
    Hellan Kwon, Anna S. Lok, Hepatitis B therapy, Nature Reviews Gastroenterology & Hepatology, 2011,

    CrossRef

  41. 41
    T. Pollicino, C. Saitta, G. Raimondo, Hepatocellular carcinoma: the point of view of the hepatitis B virus, Carcinogenesis, 2011, 32, 8, 1122

    CrossRef

  42. You have free access to this content42
    Yun-Fan Liaw, Impact of hepatitis B therapy on the long-term outcome of liver disease, Liver International, 2011, 31,
  43. 43
    Hakan Senturk, Birol Baysal, Veysel Tahan, Hasan Zerdali, Resat Ozaras, Fehmi Tabak, Ali Mert, Billur Canbakan, Omur Tabak, Gulsen Ozbay, Long-Term Effect of Interferon Therapy in Patients with HBeAg Positive Chronic Hepatitis B Infection, Digestive Diseases and Sciences, 2011, 56, 1, 208

    CrossRef

  44. 44
    Osamu Yokosuka, Masayuki Kurosaki, Fumio Imazeki, Yasuji Arase, Yasuhito Tanaka, Kazuaki Chayama, Eiji Tanaka, Hiromitsu Kumada, Namiki Izumi, Masashi Mizokami, Masatoshi Kudo, Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009, Hepatology Research, 2011, 41, 1
  45. You have free access to this content45
    Rami Moucari, Patrick Marcellin, Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B, Liver International, 2011, 31,
  46. You have free access to this content46
    V. Rijckborst, M. J. Sonneveld, H. L. A. Janssen, Review article: chronic hepatitis B – anti-viral or immunomodulatory therapy?, Alimentary Pharmacology & Therapeutics, 2011, 33, 5
  47. 47
    Masao Omata, Laurentius A. Lesmana, Ryosuke Tateishi, Pei-Jer Chen, Shi-Ming Lin, Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T. P. Poon, Shuichiro Shiina, Ann Lii Cheng, Ji-Dong Jia, Shuntaro Obi, Kwang Hyub Han, Wasim Jafri, Pierce Chow, Seng Gee Lim, Yogesh K. Chawla, Unggul Budihusodo, Rino A. Gani, C. Rinaldi Lesmana, Terawan Agus Putranto, Yun Fan Liaw, Shiv Kumar Sarin, Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma, Hepatology International, 2010, 4, 2, 439

    CrossRef

  48. 48
    Johannes Vermehren, Annika Kau, Stefan Zeuzem, Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment, Current Hepatitis Reports, 2010, 9, 2, 53

    CrossRef

  49. 49
    Massimo Colombo, Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons, Digestive and Liver Disease, 2010, 42, S298

    CrossRef

  50. 50
    Yun-Fan Liaw, Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros, Digestive and Liver Disease, 2010, 42, S293

    CrossRef

  51. 51
    Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Kenneth Kar-Lung Yan, Angel Mei-Ling Chim, Hoi-Yun Chan, Chi-Hang Tse, Paul Cheung-Lung Choi, Anthony Wing-Hung Chan, Joseph Jao-Yiu Sung, Henry Lik-Yuen Chan, Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B, Hepatology, 2010, 51, 6
  52. 52
    Ju Dong Yang, Lewis R. Roberts, Epidemiology and Management of Hepatocellular Carcinoma, Infectious Disease Clinics of North America, 2010, 24, 4, 899

    CrossRef

  53. 53
    Yun-Fan Liaw, George K. K. Lau, Jia-Horng Kao, Edward Gane, Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection, Digestive Diseases and Sciences, 2010, 55, 10, 2727

    CrossRef

  54. 54
    James Fung, Ching-Lung Lai, Man-Fung Yuen, Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B, Expert Review of Anti-infective Therapy, 2010, 8, 6, 717

    CrossRef

  55. 55
    N. Mahboobi, F. Agha-Hosseini, N. Mahboobi, S. Safari, D. Lavanchy, S-M. Alavian, Hepatitis B virus infection in dentistry: a forgotten topic, Journal of Viral Hepatitis, 2010, 17, 5
  56. 56
    Kuen-Chang Hsieh, Yu-Yawn Chen, Tsong-Rong Jang, Yu-Jen Chen, Middle-aged Subjects With Habitual Low-speed Cycling Exercise Have Greater Mononuclear Cell Responsiveness Against Human Hepatitis B Virus Surface Antigen, International Journal of Gerontology, 2010, 4, 2, 82

    CrossRef

  57. 57
    R. Moucari, P. Marcellin, Négativation de l’antigène HBs : valeur pronostique pour la réponse au traitement et l’évolution à long terme, Gastroentérologie Clinique et Biologique, 2010, 34, S119

    CrossRef

  58. 58
    Milan J. Sonneveld, Vincent Rijckborst, Charles A. B. Boucher, Bettina E. Hansen, Harry L. A. Janssen, Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline, Hepatology, 2010, 52, 4
  59. 59
    Bettina E. Hansen, Erik H.C.J. Buster, Ewout W. Steyerberg, Emmanuel Lesaffre, Harry L.A. Janssen, Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment, Journal of Medical Virology, 2010, 82, 7
  60. 60
    Milan J. Sonneveld, Harry L. A. Janssen, Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B, Current Hepatitis Reports, 2010, 9, 2, 91

    CrossRef

  61. 61
    Hui Ma, Rui-feng Yang, Lai Wei, Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients, Journal of Gastroenterology and Hepatology, 2010, 25, 9
  62. 62
    Paulo Roberto Abrão Ferreira, Simone de Barros Tenore, Response predictors to treatment with pegylated interferon in chronic hepatitis B, The Brazilian Journal of Infectious Diseases, 2010, 14, 5, 519

    CrossRef

  63. 63
    Feng Feng, Chee Quin Teoh, Qiao Qiao, David Boyle, Allison R. Jilbert, The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines, Vaccine, 2010, 28, 46, 7436

    CrossRef

  64. 64
    Vincent Rijckborst, Harry L. A. Janssen, The Role of Interferon in Hepatitis B Therapy, Current Hepatitis Reports, 2010, 9, 4, 231

    CrossRef

  65. 65
    MARGARET JAMES KOZIEL, CHLOE LYNNE THIO, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  66. 66
    Robert Perrillo, Benefits and risks of interferon therapy for hepatitis B, Hepatology, 2009, 49, S5
  67. 67
    Rami Moucari, Olivier Lada, Patrick Marcellin, Chronic hepatitis B: back to the future with HBsAg, Expert Review of Anti-infective Therapy, 2009, 7, 6, 633

    CrossRef

  68. 68
    Harry L.A. Janssen, Erik H.C.J. Buster, Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy, Journal of Hepatology, 2009, 51, 1, 224

    CrossRef

  69. 69
    Jung-mi Kim, Byung-Ho Choe, Mi Ae Chu, Seung Man Cho, Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B, The Korean Journal of Hepatology, 2009, 15, 2, 168

    CrossRef

  70. 70
    Hui-Hui Tan, Paul Martin, Current treatment of chronic HBV infection: A North American perspective, Current Hepatitis Reports, 2009, 8, 4, 148

    CrossRef

  71. 71
    Erik H C J Buster, Hajo J Flink, Halis Simsek, E Jenny Heathcote, Sachithanandan Sharmila, George E Kitis, Guido Gerken, Maria Buti, Richard A de Vries, Elke Verhey, Bettina E Hansen, Harry L A Janssen, Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients, The American Journal of Gastroenterology, 2009, 104, 10, 2449

    CrossRef

  72. 72
    Erik H.C.J. Buster, Bettina E. Hansen, George K.K. Lau, Teerha Piratvisuth, Stefan Zeuzem, Ewout W. Steyerberg, Harry L.A. Janssen, Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa, Gastroenterology, 2009, 137, 6, 2002

    CrossRef

  73. 73
    Yun-Fan Liaw, HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B, Hepatology International, 2009, 3, 3, 425

    CrossRef

  74. 74
    Pietro Lampertico, Alessio Aghemo, Mauro Viganò, Massimo Colombo, HBV and HCV Therapy, Viruses, 2009, 1, 3, 484

    CrossRef

  75. 75
    Yun-Fan Liaw, Chia-Ming Chu, Hepatitis B virus infection, The Lancet, 2009, 373, 9663, 582

    CrossRef

  76. 76
    Rami Moucari, Anneke Korevaar, Olivier Lada, Michelle Martinot-Peignoux, Nathalie Boyer, Vincent Mackiewicz, Agnes Dauvergne, Ana C. Cardoso, Tarik Asselah, Marie-Hélène Nicolas-Chanoine, Michel Vidaud, Dominique Valla, Pierre Bedossa, Patrick Marcellin, High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study, Journal of Hepatology, 2009, 50, 6, 1084

    CrossRef

  77. 77
    T. Poynard, J. Massard, M. Rudler, A. Varaud, P. Lebray, J. Moussalli, M. Munteanu, Y. Ngo, D. Thabut, Y. Benhamou, V. Ratziu, Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials, Gastroentérologie Clinique et Biologique, 2009, 33, 10-11, 916

    CrossRef

  78. 78
    Haresh Mani, David E. Kleiner, Liver biopsy findings in chronic hepatitis B, Hepatology, 2009, 49, S5
  79. 79
    Grace L.-H. Wong, Henry L.-Y. Chan, Predictors of Treatment Response in Chronic Hepatitis B, Drugs, 2009, 69, 16, 2167

    CrossRef

  80. 80
    Vincent Wai–Sun Wong, Grace Lai–Hung Wong, Angel Mei–Ling Chim, Paul Cheung–Lung Choi, Anthony Wing–Hung Chan, Steven Woon–Choy Tsang, Alex Yui Hui, Hoi–Yun Chan, Joseph Jao–Yiu Sung, Henry Lik–Yuen Chan, Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2009, 7, 10, 1113

    CrossRef

  81. 81
    Patrick Marcellin, Ferruccio Bonino, George K.K. Lau, Patrizia Farci, Cihan Yurdaydin, Teerha Piratvisuth, Rui Jin, Selim Gurel, Zhi-Meng Lu, Jian Wu, Matei Popescu, Stephanos Hadziyannis, Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a, Gastroenterology, 2009, 136, 7, 2169

    CrossRef

  82. 82
    Naoto Kawabe, Senju Hashimoto, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Yuko Arima, Naruomi Komura, Kyoko Kobayashi, Kentaro Yoshioka, The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection, Journal of Gastroenterology, 2009, 44, 7, 751

    CrossRef

  83. 83
    D.S. Miller, D. Boyle, F. Feng, G.Y. Reaiche, I. Kotlarski, R. Colonno, A.R. Jilbert, Antiviral therapy with entecavir combined with post-exposure “prime-boost” vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection, Virology, 2008, 373, 2, 329

    CrossRef

  84. 84
    R. Morillo Verdugo, A. Madrazo Berenguer, M.V. Gil Navarro, E. Suárez García, Drugs Treatment of Hepatitis B, Farmacia Hospitalaria (English Edition), 2008, 32, 4, 234

    CrossRef

  85. 85
    Henry Lik–Yuen Chan, Vincent Wai–Sun Wong, Grace Lai–Hung Wong, Angel Mei–Ling Chim, Hoi–Yun Chan, Joseph Jao–Yiu Sung, Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment, Clinical Gastroenterology and Hepatology, 2008, 6, 9, 1022

    CrossRef

  86. 86
    Emilio Palumbo, Entecavir For Chronic Hepatitis B: A Review, Therapeutic Drug Monitoring, 2008, 30, 1, 1

    CrossRef

  87. 87
    Jules L. Dienstag, Hepatitis B Virus Infection, New England Journal of Medicine, 2008, 359, 14, 1486

    CrossRef

  88. 88
    Fabien Zoulim, Robert Perrillo, Hepatitis B: Reflections on the current approach to antiviral therapy, Journal of Hepatology, 2008, 48, S2

    CrossRef

  89. 89
    Miguel Carneiro de Moura, Rui Marinho, Historia natural y manifestaciones clínicas de la hepatitis B crónica, Enfermedades Infecciosas y Microbiología Clínica, 2008, 26, 11

    CrossRef

  90. 90
    Luisa García Buey, Fernando González Mateos, Ricardo Moreno Oteroa, Interferón en la hepatitis B, Enfermedades Infecciosas y Microbiología Clínica, 2008, 26, 19

    CrossRef

  91. 91
    Emilio Palumbo, New Drugs for Chronic Hepatitis B: A Review, American Journal of Therapeutics, 2008, 15, 2, 167

    CrossRef

  92. 92
    Erik H.C.J. Buster, Solko W. Schalm, Harry L.A. Janssen, Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1093

    CrossRef

  93. 93
    J.-P. Bronowicki, A. Nani, H. Barraud, J.-F. Cadranel, Peut-on arrêter un traitement par analogue nucléos(t)idique chez un malade atteint d’hépatite chronique B ?, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S50

    CrossRef

  94. 94
    Benjamin Leader, Quentin J. Baca, David E. Golan, Protein therapeutics: a summary and pharmacological classification, Nature Reviews Drug Discovery, 2008, 7, 1, 21

    CrossRef

  95. 95
    Teerha Piratvisuth, Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B, Hepatology International, 2008, 2, 2, 140

    CrossRef

  96. 96
    Erik H.C.J. Buster, Hajo J. Flink, Yilmaz Cakaloglu, Krzysztof Simon, Jörg Trojan, Fehmi Tabak, Thomas M.K. So, S. Victor Feinman, Tomasz Mach, Ulus S. Akarca, Martin Schutten, Wanda Tielemans, Anneke J. van Vuuren, Bettina E. Hansen, Harry L.A. Janssen, Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b, Gastroenterology, 2008, 135, 2, 459

    CrossRef

  97. 97
    M. KUMAR, S. K. SARIN, Systematic review: combination therapies for treatment-naïve chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2008, 27, 12
  98. 98
    K. Luo, Q. Mao, P. Karayiannis, D. Liu, Z. Liu, Y. Zhou, X. Feng, Y. Zhu, Y. Guo, R. Jiang, F. Zhou, J. Peng, J. Hou, Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study, Journal of Viral Hepatitis, 2008, 15, 9
  99. 99
    George V Papatheodoridis, Spilios Manolakopoulos, Geoffrey Dusheiko, Athanasios J Archimandritis, Therapeutic strategies in the management of patients with chronic hepatitis B virus infection, The Lancet Infectious Diseases, 2008, 8, 3, 167

    CrossRef

  100. 100
    Ramón Planas, Rosa M. Morillas, Tratamiento de la infección por el virus de la hepatitis B. Estado actual y perspectivas, Gastroenterología y Hepatología, 2008, 31, 6, 349

    CrossRef

  101. 101
    R. Morillo Verdugo, A. Madrazo Berenguer, M.V. Gil Navarro, E. Suárez García, Tratamiento farmacológico de la hepatitis B, Farmacia Hospitalaria, 2008, 32, 4, 234

    CrossRef

  102. 102
    G. Carosi, M. Rizzetto, Treatment of chronic hepatitis B: Recommendations from an Italian workshop, Digestive and Liver Disease, 2008, 40, 8, 603

    CrossRef

  103. 103
    Annika Kau, Johannes Vermehren, Christoph Sarrazin, Treatment predictors of a sustained virologic response in hepatitis B and C, Journal of Hepatology, 2008, 49, 4, 634

    CrossRef

  104. 104
    Danbi Lee, Young-Hwa Chung, Sae Hwan Lee, Yoon-Seon Lee, Don Lee, Jeong Eun Hwang†, Kang Mo Kim, Young Suk Lim, Han Chu Lee, Eunsil Yu†, Young Sang Lee, Dong Jin Suh, Biochemical Rather than Virologic Response to Interferon Therapy may be More Closely Associated with Decrease of Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B, Gut and Liver, 2007, 1, 1, 049

    CrossRef

  105. 105
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  106. 106
    Scott T Rottinghaus, Richard J Whitley, Current non-AIDS antiviral chemotherapy, Expert Review of Anti-infective Therapy, 2007, 5, 2, 217

    CrossRef

  107. 107
    Mauricio Lisker-Melman, Gregory S. Sayuk, Defining Optimal Therapeutic Outcomes in Chronic Hepatitis, Archives of Medical Research, 2007, 38, 6, 652

    CrossRef

  108. 108
    Shoji Kubo, Hiromu Tanaka, Shigekazu Takemura, Satoshi Yamamoto, Seikan Hai, Tsuyoshi Ichikawa, Shintaro Kodai, Hiroji Shinkawa, Hiroki Sakaguchi, Akihiro Tamori, Daiki Habu, Shuhei Nishiguchi, Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus, Hepatology Research, 2007, 37, 2
  109. 109
    Teiji Kuzuya, Yoshiaki Katano, Takashi Kumada, Hidenori Toyoda, Isao Nakano, Yoshiki Hirooka, Akihiro Itoh, Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Hidemi Goto, Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2007, 22, 11
  110. 110
    Robert G. Gish, Anna S. Lok, Ting–Tsung Chang, Robert A. de Man, Adrian Gadano, José Sollano, Kwang–Hyub Han, You–Chen Chao, Shou–Dong Lee, Melissa Harris, Joanna Yang, Richard Colonno, Helena Brett–Smith, Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B, Gastroenterology, 2007, 133, 5, 1437

    CrossRef

  111. 111
    D. Sprengers, R. G. Van Der Molen, R. Binda, J. G. Kusters, R. A. De Man, H. G. M. Niesters, S. W. Schalm, H. L. A. Janssen, In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection, Journal of Viral Hepatitis, 2007, 14, 10
  112. 112
    Takashi Someya, Kenji Ikeda, Satoshi Saitoh, Masahiro Kobayashi, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada, Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis, Journal of Gastroenterology, 2007, 41, 12, 1206

    CrossRef

  113. 113
    Shi-Ming Lin, Ming-Lung Yu, Chuan-Mo Lee, Rong-Nan Chien, I-Shyan Sheen, Chia-Ming Chu, Yun-Fan Liaw, Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma, Journal of Hepatology, 2007, 46, 1, 45

    CrossRef

  114. 114
    Jay H. Hoofnagle, Edward Doo, T. Jake Liang, Russell Fleischer, Anna S.F. Lok, Management of hepatitis B: Summary of a clinical research workshop, Hepatology, 2007, 45, 4
  115. 115
    Anna Suk–Fong Lok, Navigating the Maze of Hepatitis B Treatments, Gastroenterology, 2007, 132, 4, 1586

    CrossRef

  116. 116
    Emmet B. Keeffe, Patrick Marcellin, New and Emerging Treatment of Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2007, 5, 3, 285

    CrossRef

  117. 117
    Erik H. C. J. Buster, Bettina E. Hansen, Maria Buti, Jean Delwaide, Claus Niederau, Peter P. Michielsen, Robert Flisiak, Pieter E. Zondervan, Solko W. Schalm, Harry L. A. Janssen, Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis, Hepatology, 2007, 46, 2
  118. 118
    Emmet B. Keeffe, Stefan Zeuzem, Raymond S. Koff, Douglas T. Dieterich, Rafael Esteban–Mur, Edward J. Gane, Ira M. Jacobson, Seng G. Lim, Nikolai Naoumov, Patrick Marcellin, Teerha Piratvisuth, Fabien Zoulim, Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2007, 5, 8, 890

    CrossRef

  119. 119
    Sila Cetin Akhan, Zerrin Yulugkural, Haluk Vahaboglu, Response to Interferon-Alpha in Chronic Hepatitis B Patients with and without Precore Mutant Strain and Effects on HBsAg Titers, Chemotherapy, 2007, 53, 6, 402

    CrossRef

  120. 120
    Henry Lik–Yuen Chan, Vincent Wai–Sun Wong, Ada Mei–Ling Tse, Chi–Hang Tse, Angel Mei–Ling Chim, Hoi–Yun Chan, Grace Lai–Hung Wong, Joseph Jao–Yiu Sung, Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response, Clinical Gastroenterology and Hepatology, 2007, 5, 12, 1462

    CrossRef

  121. 121
    Robert Perrillo, Hepatitis B Virus Replication x Time Equals Trouble, Gastroenterology, 2006, 130, 3, 989

    CrossRef

  122. 122
    Hitomi Sezaki, Fumitaka Suzuki, Tetsuya Hosaka, Norio Akuta, Takashi Someya, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Long-Term Follow-Up of HBeAg-Positive Young Adult Japanese Patients Treated with Corticosteroid Withdrawal Therapy for Chronic Hepatitis B, Intervirology, 2006, 49, 6, 339

    CrossRef

  123. 123
    E. Suárez García, Monitorización del tratamiento y definición de la respuesta, Gastroenterología y Hepatología, 2006, 29, 23

    CrossRef

  124. 124
    Monika Van Zonneveld, Pieter E Zondervan, Yilmaz Cakaloglu, Christopher Simon, Ulus S Akarca, Thomas MK So, Hajo J Flink, Robert A De Man, Solko W Schalm, Harry LA Janssen, Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine, Liver International, 2006, 26, 4
  125. 125
    Paul H. Hayashi, Adrian M. Di Bisceglie, The Progression of Hepatitis B– and C–Infections to Chronic Liver Disease and Hepatocellular Carcinoma: Presentation, Diagnosis, Screening, Prevention, and Treatment of Hepatocellular Carcinoma, Infectious Disease Clinics of North America, 2006, 20, 1, 1

    CrossRef

  126. 126
    Robert P. Perrillo, Therapy of hepatitis B — Viral suppression or eradication?, Hepatology, 2006, 43, S1
  127. 127
    Hajo J. Flink, Monika van Zonneveld, Bettina E. Hansen, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype, The American Journal of Gastroenterology, 2006, 101, 2, 297

    CrossRef

  128. 128
    Takeshi Okanoue, Masahito Minami, Update of research and management of hepatitis B, Journal of Gastroenterology, 2006, 41, 2, 107

    CrossRef

  129. 129
    Darren S. Miller, Michael Halpern, Ieva Kotlarski, Allison R. Jilbert, Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection, Virology, 2006, 348, 2, 297

    CrossRef

  130. 130
    Yun-Fan Liaw, Nancy Leung, Richard Guan, George K.K. Lau, Ismail Merican, Geoff McCaughan, Edward Gane, Jia-Horng Kao, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update, Liver International, 2005, 25, 3
  131. 131
    Jia-Horng Kao, Ding-Shinn Chen, Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia, Liver International, 2005, 25, 4
  132. 132
    Harry L.A. Janssen, George K.K. Lau, Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs, Hepatology, 2005, 42, 6
  133. 133
    Flor H Pujol, Marisol Devesa, Genotypic Variability of Hepatitis Viruses Associated With Chronic Infection and the Development of Hepatocellular Carcinoma, Journal of Clinical Gastroenterology, 2005, 39, 7, 611

    CrossRef

  134. 134
    Jorge A Marrero, Hepatocellular carcinoma, Current Opinion in Gastroenterology, 2005, 21, 3, 308

    CrossRef

  135. 135
    D. Sprengers, H.L.A. Janssen, Immunomodulatory therapy for chronic hepatitis B virus infection, Fundamental & Clinical Pharmacology, 2005, 19, 1
  136. 136
    Robert P. Perrillo, Long term hepatitis B therapy with lamivudine: a major step forward but can we do even better?, Journal of Hepatology, 2005, 42, 6, 953

    CrossRef

  137. 137
    Henry Lik-Yuen Chan, Alex Yui Hui, Vincent Wai-Sun Wong, Angel Mei-Ling Chim, May-Ling Wong, Joseph Jao-Yiu Sung, Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B, Hepatology, 2005, 41, 6
  138. 138
    Scott K. Fung, Anna S.F. Lok, Management of patients with hepatitis B virus-induced cirrhosis, Journal of Hepatology, 2005, 42, 1, S54

    CrossRef

  139. 139
    Gayle W Robins, Lesley J Scott, Gillian M Keating, Peginterferon-??-2a (40kD), Drugs, 2005, 65, 6, 809

    CrossRef

  140. 140
    Harry LA Janssen, Monika van Zonneveld, Hakan Senturk, Stefan Zeuzem, Ulus S Akarca, Yilmaz Cakaloglu, Christopher Simon, Thomas MK So, Guido Gerken, Robert A de Man, Hubert GM Niesters, Pieter Zondervan, Bettina Hansen, Solko W Schalm, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, The Lancet, 2005, 365, 9454, 123

    CrossRef

  141. 141
    Myoung Kuk Jang, Dae Ro Choi, Ja Young Lee, Han Kook Moon, Jun Ho Lee, Seong Man Kim, Kyung Ho Kim, Joon Yong Park, Jin Heon Lee, Hak Yang Kim, Dong Joon Kim, Myung Seok Lee, Choong Kee Park, Jae Young Yoo, Responsiveness to interferon alpha in chronic hepatitis B by presumed vertical transmission, Journal of Infection, 2005, 51, 4, 314

    CrossRef

  142. 142
    Paul H. Hayashi, Adrian M. Di Bisceglie, The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma, Medical Clinics of North America, 2005, 89, 2, 345

    CrossRef

  143. 143
    Scott K Fung, Anna S. F Lok, Update on viral hepatitis in 2004, Current Opinion in Internal Medicine, 2005, 4, 4, 359

    CrossRef

  144. 144
    Emma C Thomson, Janice Main, Advances in hepatitis B and C, Current Opinion in Infectious Diseases, 2004, 17, 5, 449

    CrossRef

  145. 145
    Hepatitis B, New England Journal of Medicine, 2004, 350, 26, 2719

    CrossRef

  146. 146
    Anna S.F. Lok, Prevention of hepatitis B virus–related hepatocellular carcinoma, Gastroenterology, 2004, 127, 5, S303

    CrossRef

  147. 147
    YUN-FAN LIAW, Role of antiviral therapy of HBV in the prevention of cirrhosis and hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2004, 19,
  148. 148
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,